Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 820 participants.

Also called NCT06987305

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 820 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06987305
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06987305. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-21 (actual); primary completion 2027-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window
Condition
Stroke, Acute Ischemic
Intervention (Drug)
Intravenous rhTNK-tPA
Intervention (Drug)
Intravenous placebo
Intervention (Procedure)
Endovascular thrombectomy
Lead sponsor
Xinqiao Hospital of Chongqing (class: other)
Collaborator
The First Affiliated Hospital of Nanchang University (class: other)
Collaborator
China Shijiazhuang Pharmaceutical Company RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD (class: not stated)

Record details

Record id
cardio:ct-nct06987305
Content hash
7af972acd92721fe4360dcc24fc67aa548973023a4297ea716a9a34b2693971c